Friends of Cancer Research has a half-day conference (hybrid, with streaming), on Tuesday, February 4, 2025. Register here:
In person, it's 10 am - 2 pm ET, at DC Ritz Carlton. I've also cut-pasted the agenda at bottom of this blog.
##
See their recent publication on validity of whole slide imaging for AI-Her2 interpretations:
https://www.discoveriesinhealthpolicy.com/2024/12/friends-of-cancer-research-whole-slide.html
##
Friends of Cancer Research is hosting a meeting focused on driving innovation in diagnostics and regulatory policy.
Key discussions will highlight evidence generation for novel technologies for diagnostic testing, including digital pathology and artificial intelligence (AI), along with strategies for developing diagnostic tests for rare biomarkers and addressing future regulatory considerations for cutting-edge tools.
New data will be released from the ongoing Digital PATH Project, which leveraged a common dataset to evaluate variability across digital pathology platforms. This meeting brings together key thought leaders to explore how these innovations can accelerate progress in precision medicine and improve patient outcomes.
10:00AM: Welcoming Remarks
10:05AM: Morning Keynote / Michelle Tarver, Director, CDRH, U.S. FDA
10:30AM: Panel 1 Discussion: Evaluating Digital Pathology and AI in Diagnostics
11:45AM: Panel 2 Discussion: Validating Diagnostic Tests for Rare Biomarkers
12:45PM: Lunch
1:15PM: Panel 3 Discussion: Advancing Regulatory Frameworks and Policies for AI in Healthcare
1:55PM: Closing Remarks
###
SIDEBAR:
You might enjoy Glass et al, Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2–Stained Clinical Specimens in Breast Cancer, Arch Path Lab Med here.
- Concluding, Automated image analysis for HER2 scoring is consistent and reliable using this algorithm. Deployment of the HER2 quality control tool across 3 clinical laboratories revealed interlaboratory variability in HER2 scoring and inconsistencies in data reporting.
- These results support the future incorporation of quality control algorithms for real-time monitoring of clinical laboratories contributing to clinical trials in oncology and in the real-world setting of HER2 immunohistochemistry testing in local clinical laboratories and hospitals.
And at the same journal, see "Introduction to Generative Artificial Intelligence; Contextualizing the Future," Singh et al., here. [One of a series].
###
SIDEBAR:
AI Corner
Chat GPT took the agenda and wrote a fictional article about the conference "as if" in the voice of a journalist who had already attended it. Find this here.
